Abstract:Lung cancer has emerged as a leading cause of cancer death in the world. Non-small cell lung cancer (NSCLC) accounts for 75–80% of all lung cancers. Current therapies are ineffective, thus new approaches are needed to improve the therapeutic ratio. Double stranded RNA (dsRNA) -mediated RNA interference (RNAi) has shown promise in gene silencing, the potential of which in developing new methods for the therapy of NSCLC needs to be tested. We report here RNAi induced effective silencing of the epidermal growth factor receptor (EGFR) gene, which is over expressed in NSCLC. NSCLC cell lines A549 and SPC-A1 were transfected with sequence- specific dsRNA as well as various controls. Immune fluorescent labeling and flow cytometry were used to monitor the reduction in the production of EGFR protein. Quantitative reverse-transcriptase PCR was used to detect the level of EGFR mRNA. Cell count, colony assay, scratch assay, MTT assay in vitro and tumor growth assay in athymic nude mice in vivo were used to assess the functional effects of EGFR silencing on tumor cell growth and proliferation. Our data showed transfection of NSCLC cells with dsRNA resulted in sequence specific silencing of EGFR with 71.31% and 71.78 % decreases in EGFR protein production and 37.04% and 54.92% in mRNA transcription in A549 and SPC-A1 cells respectively. The decrease in EGFR protein production caused significant growth inhibition, i.e.: reducing the total cell numbers by 85.0% and 78.3 %, and colony forming numbers by 63.3% and 66.8%. These effects greatly retarded the migration of NSCLC cells by more than 80% both at 24 h and at 48 h, and enhanced chemo-sensitivity to cisplatin by four-fold in A549 cells and seven-fold in SPC-A1. Furthermore, dsRNA specific for EGFR inhibited tumor growth in vivo both in size by 75.06 % and in weight by 73.08 %. Our data demonstrate a new therapeutic effect of sequence specific suppression of EGFR gene expression by RNAi, enabling inhibition of tumor proliferation and growth. However, in vivo use of dsRNA for gene transfer to tumor cells would be limited because dsRNA would be quickly degraded once delivered in vivo. We thus tested a new bovine lentiviral vector and showed lentivector-mediated RNAi effects were efficient and specific. Combining RNAi with this gene delivery system may enable us to develop RNAi for silencing EGFR into an effective therapy for NSCLC.

Gene silencing in alveolar type II cells using cell-specific promoter in vitro and in vivo.

Intratracheal Administration of siRNA Triggers mRNA Silencing in the Lung to Modulate T Cell Immune Response and Lung Inflammation.

Gene silencing in mammalian cells by PCR-based short hairpin RNA.

Application of RNA Interference in Mammalian Cells

Silencing the Epidermal Growth Factor Receptor Gene with RNAi May Be Developed As a Potential Therapy for Non Small Cell Lung Cancer.

Stable suppression of gene expression by RNAi in mammalian cells

Antitumor effect of RNA interference on non-small cell lung cancer in vivo

A DNA vector-based RNAi technology to suppress gene expression in mammalian cells

A lentivirus-based system to functionally silence genes in primary mammalian cells, stem cells and transgenic mice by RNA interference

Modulation of Gene Expression by Lentiviral-Mediated Delivery of Small Interfering RNA

Inducible Suppression of Fgfr2 and Survivin in ES Cells Using a Combination of the RNA Interference (rnai) and the Cre-LoxP System

siRNA, miRNA, and shRNA: in vivo Applications

Antitumor Effect of RNA Interference on Non-Small-cell Lung Cancer in Vivo

Specific inhibition of gene expression by small double-stranded RNAs in invertebrate and vertebrate systems

A More Efficient RNAi Inducible System for Tight Regulation of Gene Expression in Mammalian Cells and Xenograft Animals.

RNA interference with small hairpin RNAs transcribed from a human U6 promoter-driven DNA vector.

[RNA interference directed by small hairpin RNA expressed in COS-7 cells]

Downregulation enhanced green fluorescence protein gene expression by RNA interference in mammalian cells.

In vivo self-assembled small RNAs as a new generation of RNAi therapeutics

Artificial Small RNA for Sequence Specific Cleavage of Target RNA Through RNase III Endonuclease Dicer

RNA-guided transcriptional silencing in vivo with S. aureus CRISPR-Cas9 repressors